Method for preparing a diafiltered stabilized blood product

• US 6,139,878 A
• Filed: 04/27/1998
• Issued: 10/31/2000
• Est. Priority Date: 04/27/1998
• Status: Expired due to Term

• Current Assignee: CSL Behring LLC (CSL Limited)
• Original Assignee: Aventis Behring LLC (Sanofi )
• Inventors: Roth, Nathan, Berhe, Aberash, Even, Mark, Summaria, Louis
• Primary Examiner(s): Witz, Jean C.
• Application Number:
  US09/066,694
• Time in Patent Office: 918 Days
• Field of Search: 424/529, 424/532, 424/533, 435/2
• US Class Current: 424/529
• CPC Class Codes: A61K 35/14 Blood; Artificial blood perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42
• CPC Class Codes: A61L 2/0017 Filtration
• CPC Class Codes: A61M 1/3413 Diafiltration
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

A method using diafiltration to prepare a blood product is described. The method removes contaminating plasma proteins from whole blood or blood products. Diafiltration may be used on paraformaldehyde-fixed platelets to remove formaldehyde to undetectable levels, and to suspend the platelets into a formulation buffer suitable for subsequent treatment, such as lyophilization. The manufacturing procedure can be divided into three steps, a first diafiltration, fixation, preferably with paraformaldehyde, and a second diafiltration. In the first step, plasma proteins are removed from fresh or stored platelets or blood cells. The technique is gentle to prevent the activation and aggregation of the platelets. Fixation stabilizes the platelets to withstand freezing, lyophilization and subsequent reconstitution, and also provides a viral and bacterial reduction. The second diafiltration removes the paraformaldehyde to undetectable levels, and suspends the platelets or blood cells into a formulation buffer for subsequent lyophilization.

Claims

1. A method of preparing a stabilized cellular blood product by diafiltering a starting material to produce a cellular retentate and a filtrate, the method comprising diafiltering the starting material against at least one exchange of a buffer, wherein the starting material comprises whole blood or a blood product, the cellular retentate comprises a diafiltered stabilized cellular blood product, and the filtrate comprises contaminating plasma proteins.

2. The method of claim 1 wherein the whole blood is collected from a mammalian source.

3. The method of claim 2 wherein the whole blood is collected from a human source.

12. The method of claim 1, further comprising the step of reducing viral and bacterial activities of the retentate.

13. The method of claim 12, wherein the retentate comprises platelets, and the step of reducing viral and bacterial activities comprises fixing the platelets to produced fixed platelets.

14. The method of claim 13, wherein the fixed platelets are diafiltered against saline.

15. The method of claim 13, further comprising the step of adding a buffered saline solution to the fixed platelets.

16. The method of claim 15, wherein the buffered saline solution is imidazole buffered saline.

17. The method of claim 1, wherein the buffer is citrated saline.

18. The method of claim 17, wherein the starting material is diafiltered against between about 8 to about 11 exchanges of citrated saline.

19. The method of claim 18, wherein the retentate contains plasma proteins at a level of less than about 0.15 mg/mL.

20. The method of claim 1, further comprising the step of concentrating the cellular retentate.

4. A method of preparing a stabilized blood product by diafiltering a starting material to produce a retentate and a filtrate, the method comprising diafiltering the starting material against at least one exchange of a buffer, wherein the starting material comprises platelet-rich plasma or platelet concentrate, the retentate comprises a diafiltered stabilized blood product, and the filtrate comprises contaminating plasma proteins.

5. The method of claim 4 wherein the buffer contains a platelet inhibitor or an anticoagulant.

6. The method of claim 5 wherein the platelet inhibitor is selected from the group consisting of heparin, antithrombin, hirudin, prostaglandin, and theophylline.

7. The method of claim 5 wherein the anticoagulant is selected from the group consisting of EDTA, EGTA, and citrate.

8. The method of claim 4 wherein the diafiltered stabilized blood product comprises blood platelets, blood cells, or a mixture of blood platelets and blood cells.

9. A method of preparing a stabilized blood product by diafiltering a starting material to produce a cellular retentate and a filtrate, the method comprising:

diafiltering the starting material against at least one exchange of a buffer, wherein the starting material comprises whole blood or a blood product, the cellular retentate comprises a diafiltered blood product, and the filtrate comprises contaminating plasma proteins; and

stabilizing the cellular retentate.

10. The method of claim 9, wherein the step of stabilizing comprises adding to the retentate amino acids, albumin, trehalose, antifreeze proteins, monosaccharides, disaccharides, or inhibitors.

11. The method of claim 9, wherein the step of stabilizing comprises fixation of the cellular retentate.